Log in
Parasympathomimetic (direct cholinergic agonist)

Acetylcholine

Acetylcholine is an endogenous neurotransmitter at muscarinic and nicotinic receptors throughout the autonomic and somatic nervous systems. As an exogenous pharmaceutical agent, it is used as a direct-acting miotic during intraocular surgery to produce rapid pupillary constriction. The most testable fact is that acetylcholine is rapidly hydrolyzed by acetylcholinesterase, limiting its systemic use to topical ophthalmic applications.

Practice questionsHigh-yield facts
Drug classDirect cholinergic agonist, parasympathomimetic
MechanismBinds muscarinic and nicotinic receptors, mimics parasympathetic stimulation
Main usesIntraocular miosis during cataract surgery and anterior segment procedures
Key adverse effectBradycardia, bronchospasm if systemically absorbed
5 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Acetylcholine is the principal neurotransmitter of the parasympathetic nervous system and functions at both muscarinic and nicotinic cholinergic receptors.

Muscarinic effects

Binding to M3 receptors on the iris sphincter muscle causes contraction and miosis. M2 receptor activation in the heart produces negative chronotropic and inotropic effects. M3 receptors in smooth muscle of bronchi, bladder, and gastrointestinal tract cause contraction. Glandular M3 receptors increase secretions (salivary, lacrimal, bronchial).

Nicotinic effects

At the neuromuscular junction, acetylcholine binds nicotinic receptors (Nm) to depolarize skeletal muscle. At autonomic ganglia, it activates neuronal nicotinic receptors (Nn) in both sympathetic and parasympathetic pathways.

Pharmacological limitation

Acetylcholine is rapidly hydrolyzed by acetylcholinesterase (AChE) and plasma pseudocholinesterase, with a half-life measured in seconds. This makes systemic administration impractical; the pharmaceutical formulation is used only for direct intraocular instillation where high local concentrations achieve rapid miosis before significant degradation occurs.

High-yield for exams
  • Acetylcholine is rapidly hydrolyzed by acetylcholinesterase, preventing systemic therapeutic use
  • Pharmaceutical use limited to intraocular instillation during cataract and anterior segment surgery
  • Produces miosis within seconds by activating M3 muscarinic receptors on iris sphincter muscle
  • Systemic absorption (rare) can cause bradycardia, bronchospasm, and SLUDGE syndrome
  • Contraindicated in acute iritis and caution in asthma due to bronchoconstriction risk
  • Potentiated by cholinesterase inhibitors (organophosphates, donepezil, neostigmine)
  • Must be reconstituted immediately before use; cannot be stored due to instability
  • Classic prototype for cholinergic pharmacology: acts at both muscarinic and nicotinic receptors

Indications

Acetylcholine chloride intraocular solution is indicated exclusively for ophthalmic surgical use:

  • Cataract extraction – to produce complete miosis after lens delivery
  • Penetrating keratoplasty – to constrict the pupil during corneal transplantation
  • Iridectomy – to facilitate surgical access
  • Anterior segment surgery – any procedure requiring rapid, reliable miosis

The drug is instilled directly into the anterior chamber at the completion of lens extraction or at the surgeon's discretion. It produces miosis within seconds. Acetylcholine has no role in chronic glaucoma management or outpatient use due to its instability and route-specific formulation.

Pharmacokinetics

Absorption and distribution

Acetylcholine is administered as an intraocular irrigation solution and acts locally within the anterior chamber. Systemic absorption from the eye is minimal but can occur, particularly if aqueous drainage pathways are compromised.

Metabolism

Acetylcholine is hydrolyzed almost instantly by acetylcholinesterase present in the eye and plasma. The breakdown products are choline and acetate, both endogenous and non-toxic. This rapid enzymatic degradation prevents accumulation and limits duration of action to minutes after instillation.

Excretion

Metabolites are incorporated into normal biochemical pathways. No renal or hepatic dose adjustments are relevant given the topical, intraoperative route and instantaneous metabolism.

Special considerations

The pharmaceutical formulation is unstable and must be reconstituted immediately before use. It cannot be stored after preparation.

Adverse effects

When used correctly as an intraocular agent, acetylcholine is well tolerated. Adverse effects are usually related to systemic absorption or hypersensitivity.

Ocular effects

  • Transient lens opacity (rare)
  • Corneal edema
  • Corneal clouding or decompensation in compromised endothelium

Systemic effects (rare, from absorption)

  • Cardiovascular: Bradycardia, hypotension, flushing, cardiac arrhythmias
  • Respiratory: Bronchospasm, dyspnea (especially in asthmatics)
  • Gastrointestinal: Nausea, vomiting, abdominal cramping, diarrhea
  • Other: Sweating, salivation, lacrimation (cholinergic crisis if severe)

Serious reactions

Systemic cholinergic toxicity is theoretically possible but exceedingly rare given the route and rapid metabolism. It would present as SLUDGE syndrome: Salivation, Lacrimation, Urination, Defecation, Gastrointestinal upset, Emesis.

Hypersensitivity reactions including anaphylaxis have been reported rarely.

Contraindications and warnings

Absolute contraindications

  • Known hypersensitivity to acetylcholine chloride or any formulation component

Relative contraindications and cautions

  • Acute iritis or acute uveitis – may exacerbate inflammation
  • Corneal endothelial compromise – risk of corneal decompensation
  • Severe cardiovascular disease – bradycardia or heart block may worsen
  • Asthma or chronic obstructive pulmonary disease – bronchospasm risk if systemically absorbed
  • Hyperthyroidism – cholinergic stimulation may precipitate crisis
  • Gastrointestinal obstruction or peptic ulcer disease – increased motility and secretion
  • Urinary tract obstruction – detrusor contraction may worsen obstruction

Pregnancy and lactation

No adequate studies exist. The intraocular route and rapid metabolism suggest negligible fetal exposure, but use only if clearly needed. Excretion into breast milk is unlikely given the route and metabolism.

Pediatric and geriatric use

Safety and efficacy in pediatric populations have not been formally established, though the drug has been used in pediatric cataract surgery. No specific geriatric precautions beyond underlying comorbidities.

Drug interactions

Cholinesterase inhibitors

Concurrent use of systemic anticholinesterases (e.g., neostigmine, pyridostigmine, donepezil, rivastigmine) or exposure to organophosphate pesticides potentiates acetylcholine effects by preventing its breakdown. This can lead to prolonged miosis and increased risk of systemic cholinergic toxicity.

Anticholinergic agents

Atropine, scopolamine, and other muscarinic antagonists directly oppose acetylcholine's miotic effect. Preoperative or concurrent use may reduce efficacy.

Topical NSAIDs

Nonsteroidal anti-inflammatory ophthalmic drops do not have a direct pharmacokinetic interaction but may be used concurrently in surgical protocols without issue.

Anesthetic agents

Succinylcholine (a depolarizing neuromuscular blocker) is also metabolized by pseudocholinesterase. In patients with pseudocholinesterase deficiency or taking cholinesterase inhibitors, both drugs may have prolonged effects, though acetylcholine's intraocular route minimizes this interaction clinically.

Beta-blockers

Systemically absorbed acetylcholine could theoretically enhance bradycardia in patients on beta-blockers, but this is exceedingly rare given the limited systemic exposure.

Clinical pearls

  • USMLE favorite: Acetylcholine is the classic example of a drug with no systemic therapeutic use due to rapid enzymatic degradation and non-selective receptor activation. Its pharmaceutical use is restricted to direct topical instillation in the eye.
  • Reconstitution required: The drug is supplied as a two-vial system requiring sterile reconstitution immediately before use; it cannot be autoclaved or stored.
  • Rapid onset: Miosis occurs within seconds of anterior chamber instillation, making it ideal for intraoperative pupil control. Effect lasts several minutes.
  • Cholinergic agonist prototype: Acetylcholine is the reference compound for understanding cholinergic pharmacology. Direct agonists (bethanechol, pilocarpine) and indirect agonists (cholinesterase inhibitors) are compared to acetylcholine's activity.
  • SLUDGE mnemonic applies: Though rare with intraocular use, systemic cholinergic excess produces the SLUDGE toxidrome, treated with atropine.
  • Compare to carbachol: Carbachol is a more stable alternative miotic used intraocularly. It resists cholinesterase degradation and has a longer duration of action, but acetylcholine's rapid offset may be preferable in certain surgical scenarios.
  • Not for glaucoma: Unlike pilocarpine (a stable muscarinic agonist used chronically for glaucoma), acetylcholine's instability limits it to single intraoperative use.
  • Neurotransmitter vs. drug: Students must distinguish endogenous acetylcholine (ubiquitous neurotransmitter) from exogenous pharmaceutical acetylcholine (niche ophthalmic agent). Exam questions often test this distinction.
Mnemonic

SLUDGE syndrome (cholinergic excess): Salivation, Lacrimation, Urination, Defecation, Gastrointestinal upset, Emesis

Practice questions

1. A 68-year-old man undergoes cataract extraction with intraocular lens implantation. At the completion of lens delivery, the surgeon instills acetylcholine chloride into the anterior chamber to achieve miosis. Within 30 seconds, the patient develops bradycardia (heart rate 45/min) and begins wheezing. Which of the following properties of acetylcholine best explains why systemic effects are rare with this route of administration?

Answer: B. Acetylcholine is rapidly hydrolyzed by acetylcholinesterase (and plasma pseudocholinesterase) within seconds, which normally prevents systemic effects even if small amounts are absorbed from the anterior chamber. This patient's reaction suggests either unusually high systemic absorption or a deficiency in cholinesterase activity. Acetylcholine does not undergo first-pass metabolism because it is not given orally, and it is not selectively M3—it acts at all muscarinic and nicotinic receptors, which is why systemic absorption causes bradycardia (M2) and bronchospasm (M3).

2. A 45-year-old woman with myasthenia gravis treated with pyridostigmine is scheduled for corneal transplantation. The surgeon plans to use acetylcholine intraocularly for miosis. Which of the following effects is most likely to be potentiated in this patient?

Answer: B. Pyridostigmine is an acetylcholinesterase inhibitor that prevents the breakdown of acetylcholine, thereby potentiating and prolonging its effects. When exogenous acetylcholine is instilled intraocularly in a patient taking pyridostigmine, the miotic effect will be enhanced and last longer than expected because the drug cannot be hydrolyzed as rapidly. While option A is also theoretically true (both drugs are metabolized by cholinesterases), the question asks about the effect of acetylcholine specifically, making option B the best answer. Acetylcholine causes miosis, not mydriasis, and decreases (not increases) intraocular pressure.

3. A pharmaceutical company is developing a new miotic agent for intraoperative use. Compared to acetylcholine, the ideal new agent would have which of the following properties?

Answer: B. The major limitation of acetylcholine as a pharmaceutical agent is its rapid degradation by cholinesterases, requiring immediate reconstitution and limiting its duration of action. An improved miotic agent would be resistant to cholinesterase degradation, allowing for better stability, longer shelf life, and prolonged duration of effect (like carbachol). Acetylcholine already has nearly instantaneous onset, so faster action is unnecessary. Nicotinic activation would cause unwanted neuromuscular and autonomic ganglionic effects. Greater systemic absorption would increase adverse effects rather than improve efficacy for a topical ophthalmic agent.

Frequently asked questions

How does acetylcholine work?

Acetylcholine works by binding to muscarinic and nicotinic cholinergic receptors, mimicking parasympathetic nervous system activity. In ophthalmic use, it activates M3 muscarinic receptors on the iris sphincter muscle, causing contraction and rapid miosis (pupil constriction). It is hydrolyzed within seconds by acetylcholinesterase, limiting its action to the site of administration. Systemically, it would stimulate parasympathetic effects including decreased heart rate, bronchoconstriction, increased GI motility, and glandular secretion, but this rapid metabolism prevents therapeutic systemic use.

What are the side effects of acetylcholine?

When used as an intraocular agent, acetylcholine is generally well tolerated with minimal side effects. Rare ocular effects include transient lens opacity and corneal edema. Systemic side effects are uncommon but can occur if the drug is absorbed, including bradycardia, hypotension, bronchospasm (especially in asthmatics), nausea, vomiting, sweating, and salivation. Severe systemic absorption could theoretically cause cholinergic crisis (SLUDGE syndrome), but this is exceedingly rare given the intraocular route and rapid enzymatic breakdown by acetylcholinesterase.

Is acetylcholine a controlled substance?

No, acetylcholine is not a controlled substance. It is a prescription medication classified as a parasympathomimetic agent used exclusively in ophthalmic surgery. It has no abuse potential and is not regulated under the Controlled Substances Act. The drug is supplied as a sterile ophthalmic solution for intraocular use during procedures like cataract extraction, and its use is restricted to the surgical setting due to its instability and the need for immediate reconstitution before administration.

Acetylcholine vs carbachol — what is the difference?

Both acetylcholine and carbachol are direct cholinergic agonists used intraocularly to produce miosis during eye surgery. The key difference is stability: acetylcholine is rapidly hydrolyzed by acetylcholinesterase within seconds, giving it a very brief duration of action, while carbachol is resistant to cholinesterase breakdown and has a longer duration (hours). Carbachol also has greater nicotinic activity. Clinically, acetylcholine provides faster onset but shorter effect, making it suitable when transient miosis is desired, whereas carbachol is preferred when prolonged pupil constriction is needed postoperatively.

Why is acetylcholine not used systemically?

Acetylcholine cannot be used systemically because it is hydrolyzed almost instantly by acetylcholinesterase and plasma pseudocholinesterase, with a half-life of only seconds. This rapid degradation prevents it from reaching target tissues in therapeutically effective concentrations when given orally, intravenously, or intramuscularly. Additionally, acetylcholine acts non-selectively at both muscarinic and nicotinic receptors throughout the body, which would cause widespread and uncontrolled parasympathetic and neuromuscular effects. Its pharmaceutical use is therefore limited to direct topical application in the anterior chamber of the eye during surgery.

Conditions it is used for

Intraoperative miosis during cataract surgeryPupil constriction during anterior segment surgeryMiosis during penetrating keratoplastyPupil management during iridectomy
CarbacholPilocarpineBethanecholMethacholineNeostigminePhysostigmineAtropineScopolamine

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: S01EB09

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.